Last reviewed · How we verify
Perindopril + amlodipine + if necessary, hydrochlorothiazide
This combination reduces blood pressure by blocking angiotensin II formation (perindopril), relaxing blood vessel smooth muscle (amlodipine), and reducing fluid volume (hydrochlorothiazide).
This combination reduces blood pressure by blocking angiotensin II formation (perindopril), relaxing blood vessel smooth muscle (amlodipine), and reducing fluid volume (hydrochlorothiazide). Used for Hypertension (essential hypertension in patients not adequately controlled on dual therapy).
At a glance
| Generic name | Perindopril + amlodipine + if necessary, hydrochlorothiazide |
|---|---|
| Sponsor | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company |
| Drug class | ACE inhibitor + calcium channel blocker + thiazide diuretic combination |
| Target | Angiotensin-converting enzyme (ACE), L-type calcium channels, sodium-chloride cotransporter |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Perindopril is an ACE inhibitor that prevents conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Amlodipine is a calcium channel blocker that causes vasodilation by blocking calcium influx into vascular smooth muscle cells. Hydrochlorothiazide is a thiazide diuretic that reduces blood volume and sodium reabsorption in the distal convoluted tubule. Together, these agents provide complementary antihypertensive effects.
Approved indications
- Hypertension (essential hypertension in patients not adequately controlled on dual therapy)
Common side effects
- Cough
- Dizziness
- Headache
- Peripheral edema
- Fatigue
- Hyperuricemia
- Hypokalemia
- Hypotension
Key clinical trials
- Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: